PCE is pleased to announce a new strategic partnership with Magle Pharmacept, part of the Magle Group, aimed at improving treatment opportunities and outcomes for people affected by pancreatic cancer.
As part of this collaboration, Magle PharmaCept will support the Treatment Opportunities for Pancreatic Cancer project, running from 2025 to 2026. This initiative will focus on promoting innovative treatment approaches, enhancing surgical care, and improving access to solutions across Europe. It will also share best practices and key quality standards for care with a wide range of stakeholders—patients, carers, advocates, healthcare professionals, and policymakers.
“PCE is honoured to begin this new collaboration with Magle for the benefit of pancreatic cancer patients and their families,” said Maria Luisa Pagano, PCE Secretariat Coordinator. “Magle supports PCE’s activities that aim to increase patients’ awareness on pancreatic cancer and enhance their quality of life. I hope that this important partnership will grow over time.”
This partnership highlights Magle PharmaCept’s strong commitment to innovation in healthcare and its patient-first approach.
“This partnership with PCE marks a meaningful step in our aspiration to support healthcare professionals and patients navigating modern pancreatic cancer surgery,” said Helena Ossmer Thedius, Chief Marketing and Innovation Officer at Magle Group.
PCE looks forward to the positive impact this collaboration will have on the pancreatic cancer community across Europe.
Find out more here